A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Inclusion Criteria:

• Participant must be greater than or equal to (>=) 18 years of age, at the time ofsigning informed consent

• Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20positive

• Must meet the following indications for each subtype: Relapsed or refractory matureaggressive large B cell non-Hodgkin lymphoma (NHL) and follicular lymphoma Grade 3b:Participants must have had >= 2 lines of systemic therapy or >= 1 line of systemictherapy in case of participants ineligible for high-dose chemotherapy and autologoushematopoietic stem cell transplantation (HSCT); Relapsed or refractory follicularlymphoma Grade 1-3a and marginal zone lymphoma: Participants must have had >= 2prior lines of anti-neoplastic systemic therapy. Participants also must have priorexposure to an anti-CD20 monoclonal antibody

• Frontline high-risk diffuse large B Cell lymphoma (DLBCL): Participants must haveDLBCL or high-grade B-cell lymphoma (HGBCL) with residual lymphoma by positiveinterim positron emission computed tomography 2 or 3 cycles of frontlinechemoimmunotherapy. Participants must have only received 2 or 3 cycles of frontlinechemoimmunotherapy for DLBCL

• Measurable disease as defined by Lugano 2014 classification

• Eastern cooperative oncology group (ECOG) performance status of either 0 or 1. ECOGof 0 to 2 is allowed in frontline high-risk DLBCL cohort

Exclusion Criteria:

• Diagnosis of Human herpes virus (HHV) 8-positive DLBCL or T cell/histiocyte-richlarge B-cell lymphoma

• Any prior solid organ or allogeneic stem cell transplantation

• Autologous stem cell transplant within 12 weeks of chimeric antigen receptor (CAR) Tcell infusion

• Uncontrolled active infections

• History of deep vein thrombosis or pulmonary embolism within six months of infusion (except for line associated deep vein thrombosis [DVT])

• History of stroke, unstable angina, myocardial infarction, congestive heart failureNew York Heart Association (NYHA) Class III or IV, severe cardiomyopathy orventricular arrhythmia requiring medication or mechanical control within 6 months ofscreening

• History of a seizure disorder, dementia, cerebellar disease or neurodegenerativedisorder

• Known history or prior diagnosis of optic neuritis or other immunologic orinflammatory disease affecting the central nervous system

• Current active liver or biliary disease (except for Gilbert's syndrome orasymptomatic gallstones)